Cancer Moonshot℠ – Funding Opportunities

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.

Planning for implementation of longer-term scientific initiatives is also underway. We have established implementation teams aligned with the BRP recommendations. The teams include NCI extramural and intramural scientists, and experts from several other NIH institutes and centers. Team members are considering multiple ways to fund the best science, including grants, supplements, and other mechanisms, and, where appropriate, to form partnerships with foundations, academia, and the private sector. We look forward to engaging our extramural colleagues in this process.

We will continue to update this page as new funding opportunities become available. Please check back often or sign up to receive automatic email updates for these announcements and other Cancer Moonshot-related activities.

Open Funding Opportunity Announcements (FOA)
BRP Recommendation Title Announcement Number Opening Date Expiration Date
Cancer Immunotherapy Translational Science Network Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01) PAR-16-058 1/5/2016 5/8/2017
Cancer Immunotherapy Translational Science Network Metabolic Reprogramming to Improve Immunotherapy (R01) PAR-16-228 9/5/2016 9/8/2019
Cancer Immunotherapy Translational Science Network Metabolic Reprogramming to Improve Immunotherapy (R21) PAR-16-229 9/16/2016 9/8/2019
Cancer Immunotherapy Translational Science Network Canine Immunotherapy Trials and Correlative Studies (U01) RFA-CA-17-001 2/7/2017 3/8/2017
Cancer Immunotherapy Translational Science Network Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) RFA-CA-17-002 2/7/2017 3/8/2017
Cancer Immunotherapy Translational Science Network Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) RFA-CA-17-015 2/7/2017 3/8/2017
Cancer Immunotherapy Translational Science Network Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) RFA-CA-17-016 2/7/2017 3/8/2017
Cancer Immunotherapy Translational Science Network Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) RFA-CA-17-005 2/17/2017 3/18/2017
Cancer Immunotherapy Translational Science Network Cancer Immunologic Data Common (CIDC) (U24) RFA-CA-17-006 2/17/2017 3/18/2017
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity (U54) RFA-CA-17-009 2/3/2017 3/4/2017
National Cancer Data Ecosystem PDX Development and Trial Centers (PDTCs) (U54) RFA-CA-17-003 2/3/2017 3/4/2017
National Cancer Data Ecosystem PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24) RFA-CA-17-004 2/3/2017 3/4/2017
Fusion Oncoproteins in Childhood Cancers Gene Fusions in Pediatric Sarcomas (R01) PA-16-251 9/5/2016 5/8/2019
Fusion Oncoproteins in Childhood Cancers Gene Fusions in Pediatric Sarcomas (R21) PA-16-252 9/16/2016 5/8/2019
Fusion Oncoproteins in Childhood Cancers Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) PA-17-138 3/1/2017 3/29/2018
Generation of Human Tumor Atlases Emerging Questions in Cancer Systems Biology (U01) PAR-16-131 5/24/2016 11/24/2018
New Enabling Technologies Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp) PA-17-143 3/12/2017 12/13/2017
  • Updated: February 27, 2017

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source. Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artist, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.